Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4195268 | 0.98 | KDM4E (0.43) | MEN1KMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4191948 | 0.96 | MEN1 (0.45) | MEN1KMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4191934 | 0.94 | KDM4E (0.43) | MEN1KMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4191386 | 0.89 | LMNA (0.44) | MEN1KMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4191142 | 0.87 | KDM4E (0.41) | MEN1KMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL13762167 | 0.85 | POLB (0.37) | MEN1KMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4198270 | 0.85 | KDM4E (0.48) | MEN1KMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4198529 | 0.84 | KDM4E (0.33) | MEN1KMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4188698 | 0.84 | KDM4E (0.43) | MEN1KMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL13762157 | 0.83 | LMNA (0.37) | MEN1KMT2AKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576122-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2009-08-18 | — | — | US | claimed |
| US-20060276504-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-12-07 | — | — | US | claimed |
| US-7576122-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576122-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1664011-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20080287489-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2008-11-20 | — | — | US | disclosed |
| US-20080287489-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2008-11-20 | — | — | US | disclosed |
| US-20060276504-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-12-07 | — | — | US | disclosed |
| EP-1664011-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005020917-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276504-A1 | Ophthalmic compositions for treating ocular hypertension | KCNH2, KCNJ11, KCNN1 | MEN1 917/4885KMT2A 3038/4885KDM4E 1362/4885 |
| US-20080287489-A1 | Ophthalmic compositions for treating ocular hypertension | KCNH2, KCNH3, KCNJ11 | MEN1 754/4885KMT2A 2478/4885KDM4E 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.